Key terms

About CGEM

Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CGEM news

Apr 18 12:28am ET Strategic Shift and Promising Data Underpin Buy Rating for Cullinan Management’s CLN-978 Apr 17 7:11am ET Cullinan Therapeutics price target raised to $30 from $20 at BTIG Apr 16 8:16pm ET Buy Recommendation: Cullinan Management’s Strategic Position in Autoimmune Disease Market with Promising CLN-978 Therapy Apr 16 1:30pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cullinan Management (CGEM), Johnson & Johnson (JNJ) and UnitedHealth (UNH) Apr 16 12:45pm ET Cullinan Management’s Promising Clinical Developments and Financial Prospects Warrant a Buy Rating Apr 16 12:05pm ET Cullinan Therapeutics’ Strategic Pivot to Autoimmune Diseases and Promising Outlook for CLN-978 Spurs Buy Rating Apr 16 11:53am ET Cullinan Oncology price target lowered to $29 from $34 at H.C. Wainwright Apr 16 7:32am ET Cullinan Management’s Strategic Shift and Capital Raise Apr 16 7:13am ET Cullinan Oncology changes name to Cullinan Therapeutics Apr 16 7:13am ET Cullinan Oncology announces strategic expansion into autoimmune diseases Apr 16 7:03am ET Cullinan Therapeutics announces oversubscribed $280M private placement Apr 15 8:44am ET Cullinan initiated with Outperform on oncology portfolio at William Blair Apr 15 5:45am ET Cullinan Oncology initiated with an Outperform at William Blair Mar 19 2:00am ET Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Gilead Sciences (GILD) Mar 14 3:40pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM) Mar 14 1:40pm ET Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL) Mar 14 12:25pm ET Cullinan Management: A Buy Rating on Strong Financials and Promising Clinical Trials Mar 14 12:16pm ET Cullinan Oncology announces departure of CFO Jeff Trigilio Mar 01 7:04am ET Cullinan Oncology announces U.S. FDA clearance of IND for CLN-619 Feb 15 8:12am ET Wedbush bullish on Cullinan Oncology, initiates with an Outperform Feb 14 4:05pm ET Cullinan Oncology initiated with an Outperform at Wedbush Jan 22 2:02pm ET Buy Rating Affirmed: Cullinan Management’s Innovative Pipeline Promises Market Disruption and Strategic Growth

No recent press releases are available for CGEM

CGEM Financials

1-year income & revenue

Key terms

CGEM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CGEM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms